Future Oncol. 2023 Jun 7. doi: 10.2217/fon-2023-0020. Online ahead of print.
ABSTRACT
Aim: To explore treatment selection for relapsed/refractory multiple myeloma (RRMM), which remains complex due to heterogeneity of available treatments and lack of defined standard of care. Patients & methods: The Adelphi Real World MM Disease Specific Programme surveyed physicians in the USA and their patients with MM to collect real-world data on patterns and perceptions of MM treatment across lines of therapy (LOT). Results: Triplets were the most common regimens across each LOT. Physicians reported efficacy-related factors, health insurance coverage, and clinical guidelines as key determinants of treatment choice regardless of LOT. Patients identified better quality of life as the most important treatment benefit. Conclusion: The DSP RW data highlight drivers of RRMM treatment choice from physicians’ and patients’ perspectives and need for a more holistic approach to guidelines and clinical trials that encompasses patient perspectives.
PMID:37283044 | DOI:10.2217/fon-2023-0020